Intravesical Chemotherapy for Bladder Tumors

摘要: Approximately 40,000 new cases of bladder cancer are discovered annually in the United States, with 11,000 cancer-related deaths.1 Eighty percent these tumors superficial at time presentation, involving mucosa or submucosa only and thus potentially curable by transurethral surgical resection.2 However, following complete excision, 40–80% patients papillary carcinoma will develop growths within 3 years, up to 30% progress grade stage disease.3–5 Prospective longitudinal studies have helped define natural history cancer, identifying subgroups this heterogeneous population who higher risk for recurrence progression. In past 25 addition intravesically administered chemotherapeutic immunotherapeutic agents resection has proven effective both treatment residual disease undergoing incomplete excision prophylaxis against tumor formation those whom is possible. This chapter review role intravesical control disease.